INTRODUCTION 1
Magnesium (Mg) is an essential cofactor in hundreds of enzymatic reactions in the human body (1) . Mg deficiency or insufficiency, as defined by low circulating Mg concentrations, have been associated with a variety of chronic diseases, especially cardiometabolic diseases (2) (3) (4) . Mg is found in whole grains, green leafy vegetables, legumes, and nuts (2), but is substantially lost during food refining and processing (3, 4) . Mg intake is suboptimal in the US general population (5, 6) , particularly among adolescent females, adult females, and the elderly; it is estimated that 70% of the elderly American population has a total Mg intake below the estimated average requirement (EAR) (7) . Mg is currently included in the list of shortfall nutrients in the 2015
Dietary Guidelines Advisory Committee Report (DGAC) (8) .
Accurate assessment of Mg status is crucial for clinical evaluation of Mg deficiency and associated health endpoints (9) . Although accumulating epidemiological evidence suggests significant associations between low circulating (serum/plasma) Mg concentrations or urinary Mg excretion and cardiometabolic diseases (10, 11) , it remains unclear whether and to what extent measurements of circulating or urine Mg concentrations are modifiable. Further, the effects of Mg supplementation on related nutritional biomarkers, such as calcium (Ca 2+ ) and parathyroid hormone (PTH) is unclear.
To comprehensively assess the responsiveness of Mg biomarkers and Mg-related biomarkers to oral Mg supplementation, we conducted a meta-analysis of randomized controlled trials (RCTs), to assess their dose-and time-responses to Mg supplementation. In addition, we explored potential sources of between-study heterogeneity by pre-specified factors that may influence Mg status responsiveness, such as age, sex, ethnicities, baseline Mg status, cardiometabolic health status (diabetes, hypertension, or cardiovascular disease), Mg formulation, trial sample size, and quality.
METHODS

Search strategy
We followed PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines for meta-analyses of RCTs (12) . Searches were conducted in MEDLINE and the Cochrane Library up to November 1, 2014. The words of "magnesium", "Mg", "supplementation", "supplement", "intervention", "depletion", "randomized controlled trial", "randomized clinical trial", "randomized trial", "controlled trial", and "clinical trial" were used in article texts and MeSH (Medical Subject Headings) terms in searches. We also manually searched additional eligible trials from the references of relevant original or review papers. All searches were limited to articles published in English.
Selection criteria
We included RCTs of oral Mg supplementation in adults, which evaluated Mg biomarkers at baseline and after the intervention. Exclusion criteria are listed as follows: 1) studies involving pregnant or lactating women; 2) non-randomized, open-label, or uncontrolled studies; and 3) studies of patients with malignancy, severe anemia, severe infectious disease, severe liver or renal diseases, and other severe illnesses, as these disease conditions might directly or indirectly affect normal Mg metabolism. Studies that used combination supplements with Mg in the intervention group were eligible only if the same combined supplements without Mg were included in the control group. Trials comparing multiple micronutrients containing Mg to placebo/blank controls were ineligible.
Study selection
Two authors (X Zhang and Y Song) independently examined the title and abstract of each article to remove irrelevant and duplicated results first. Then, any articles deemed potentially eligible underwent a full-text review and their eligibilities were assessed based on the same inclusion and exclusion criteria. Any discrepancies were resolved through discussion.
Data extraction
From each included study, we extracted available data on first author's name, year of publication and country, sex, mean age or age range, number of participants, comorbidities, combination therapy, baseline dietary Mg level, study design, trial duration, formulation and dose of Mg supplements, types of Mg biomarkers assessed, and means and standard deviations (SD) of biomarkers in both Mg and control groups before and after supplementation.
One study compared multiple dose intervention groups with a single placebo or control group. To avoid correlation error and multiple comparisons, we divided the shared control group into 2 independent small groups with the means and SDs weighted by the corresponding sample sizes of intervention groups (13) . If repeated measures of Mg biomarker at several time points were reported in a single trial, the values at the end of the study were selected for overall metaanalysis; however, both were included in subgroup analyses when estimates were stratified into separate groups by pre-specified factors.
Assessment of risk of bias
Trial quality was evaluated according to the Agency for Healthcare Research & Quality (AHRQ) criteria for quality assessment of RCTs (14, 15) . The evaluation criteria include adequate sequence generation for randomization, allocation concealment, blinding of outcomes assessors, similarity of groups at baseline, selective reporting, incomplete outcome data, and description of losses and exclusions. Each study was judged to be of either high, low, or unclear risk for each criterion. In order to evaluate the potential confounding effect from trial quality, we also calculated a 5-item Jadad Score (16, 17) and rated each individual trial as being of either low (< 4) or high quality (≥ 4).
Statistical methods
The A two-tailed P < 0.05 was considered statistically significant. Stata (Version 13; StataCorp, College Station, TX) was used for all statistical analyses.
RESULTS
Our systematic search initially identified 1,766 articles (Figure 1 Of 35 identified biomarkers, serum and plasma Mg were most commonly used (41 trials), followed by 24-h urine Mg (24 trials), red blood cell Mg (9 trials), and ionized Mg (5 trials).
Only a few articles evaluated Mg status in other compartments, such as muscle, intracellular, saliva, hair, feces, and brain tissue (Figure 1) . Additionally, 16 publications provided data on biomarkers indirectly related to Mg status, including calcium, potassium, and sodium concentrations in serum/plasma or urine, serum Ca/Mg ratio, PTH, and plasma renin activity (PRA).
Circulating Mg concentrations
Circulating Mg (serum or plasma) was most common biomarker assayed (41 trials), accounting for 87% of eligible articles (941 participants in treatment and 953 in control arms).
After Table 1) . A similar dose of 300 mg/d was used in all these 9 trials, which could not allow us to examine the dose-response relationship for RBC Mg.
Ionized Mg
Only 5 and placebo groups were observed (23, 24) .
Other Mg biomarkers in blood, urine, or other specimens
As only a few trials examined intravenous (IV) Mg load, Mg balance, Mg retention, and mononuclear Mg, insufficient data were available for a meta-analysis of these biomarkers ( Table   1) .
Mg in other tissues such as intracellular (4 trials), muscle (2 trials), feces (2 trials), hair (1 trial), saliva (1 trial), and brain tissue (1 trial) were also assessed. Among these biomarkers, only fecal Mg concentrations were significantly elevated compared with placebo group after supplementation; the SMD based on 2 trials was 3.57 (95% CI: 1.59, 5.56) ( Table 1 ). In addition, two trials evaluated muscle Mg concentrations, but no significant changes in this biomarker were observed (WMD: -0.20 mmol/L; 95% CI: -0.50, 0.10).
Other Mg status-related biomarkers
Among circulating and urine calcium, sodium, and potassium ( 
Dose-and time-dependent responses of circulating and urine Mg concentrations
Heterogeneity
Between-study heterogeneity was high for circulating Mg, RBC Mg, urine Mg, and ionized
Mg; all P-values from Q-tests were <0.0001 (all I 2 >80%) ( Table 1 ). Sensitivity analysis showed that the overall results were robust and no single study affected the meta-analytic estimate by more than 5%.
Although no significant heterogeneity was observed by specific supplement formulation Mg loading test (28, 29 Other tissue Mg concentrations such as muscle, saliva, hair, fecal, and brain tissues were also reported in some trials. However, sensitivity of these biomarkers to Mg supplementation requires more data. Co-existence of secondary electrolyte abnormalities may play a key role in the clinical features of Mg depletion (36) . For instance, calcium, potassium, and sodium in blood and urine were frequently assessed, and urine calcium concentrations appear to be more sensitive to Mg supplementation than others based on the present analysis. Despite some biological evidence suggesting that hypomagnesemia may interfere with the hypocalcaemia-induced PTH release (37, 38) , our analysis based on 3 RCTs showed that Mg supplementation did not significantly affect PTH concentrations.
Our meta-analysis has several strengths. Our quantitative assessment was based on data from RCTs largely of high-quality, which excluded open-label and one-arm trials, thereby minimizing selection bias and other biases. Our comprehensive search strategy make it unlikely that any major published trials were missed. The quality of all trials were formally evaluated by AHRQ criteria and Jada score to assess the influence of overall trial quality on the results. We also systematically reviewed both direct and indirect Mg-status related biomarkers, and addressed dose-and time-response of Mg biomarkers to Mg supplementation for the first time.
Several limitations warrant consideration. First, although a large number of randomized trials were included in our meta-analysis, few trials for biomarkers other than circulating and urine Mg was available, such as ionized Mg, and Mg in muscle, saliva and other tissues. Second, the presence of substantial between-study heterogeneity in the main meta-analyses could add uncertainty to estimates. However, we conducted several subgroup analyses stratified by many pre-specified factors, such as baseline Mg status, and organic vs. inorganic formulation, which contributed to significant heterogeneity of results. Third, trials with larger sample sizes and longer durations are clearly lacking. Fourth, influence by inadequate sequence generation and allocation concealment as well as compliance could not be assessed due to a lack of relevant information in most of included RCTs. Finally, as in any meta-analysis of published results, publication bias is possible, although we did not find any evidence of publication bias based on Egger's or Begg's tests.
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FIGURE 2. Distributions of circulating Mg concentrations (A) and 24-h urine Mg excretion (B)
among participants in the treatment groups before and after Mg supplementation. 
